Serum adiponectin in breast cancer: A meta-analysis.

Abstract

BACKGROUND:

Accumulating data have found that adiponectin is involved in development of breast cancer (BC). However, these results were inconsistent.

METHOD:

A systematic search in PubMed, Embase, ISI Web of Science, and Chinese National Knowledge Infrastructure databases were conducted up to October 1, 2017. The standardized mean difference (SMD) with 95% confidence interval was applied to pool the effect size.

RESULTS:

Finally, 31 eligible studies were included in this meta-analysis. The overall results indicated that serum adiponectin levels in BC cases were significantly lower than the controls (SMD = -0.33, P < 0.0001). As for the subgroup analysis of menstrual status, serum adiponectin levels were significantly lower in pre- and postmenopausal BC cases. Moreover, the subgroup analysis by ethnicity in pre- and postmenopausal group indicated an inverse association between adiponectin levels and BC risk in Asian population, but not in Caucasian population.

CONCLUSION:

The present meta-analysis suggests that low serum adiponectin concentration may be associated with an increased BC risk in premenopausal and postmenopausal women, especially among Asians. Adiponectin may serve as a biomarker of BC risk and help to identify subjects at high risk for BC development.

• Authors: Li Gu, Chang Cao, Jing Fu, Qian Li, De-Hua Li, Ming-Yao Chen
• Journal: Medicine (Medicine (Baltimore)) Vol. 97 Issue 29 Pg. e11433 (Jul 2018) ISSN: 1536-5964 [Electronic] United States
• PMID: 30024516 (Publication Type: Journal Article, Meta-Analysis, Review)

Chemical References

• ADIPOQ protein, human
• Adiponectin
• Biomarkers

Topics

• Adiponectin (blood)
• Biomarkers (blood)
• Breast Neoplasms (blood)
• Female
• Humans
• Risk Factors